StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sarepta Therapeutics (SRPT) PT Raised to $215 at RBC Capital; 'Vynodys Approval A Big Win'
December 13, 2019 6:19 AM
RBC Capital analyst Brian Abrahams raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $215.00 (from $200.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Sarepta Therapeutics (SRPT) PT Raised to $190 at Credit Suisse
December 13, 2019 7:44 AM
Sarepta Therapeutics (SRPT) PT Raised to $270 at JMP Securities
December 13, 2019 4:38 AM
Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53
December 12, 2019 6:18 PM
After-Hours Movers 12/12: (SRPT) (IHRT) (ADBE) Higher; (UTI) (ASPU) (ORCL) Lower (more...)
December 12, 2019 5:54 PM
Sarepta Therapeutics (SRPT) halted, news pending
December 12, 2019 5:52 PM
Sarepta Therapeutics (SRPT) Vyondys 53 Granted Accelerated FDA Approval to Treat DMD
December 12, 2019 5:49 PM
